"Successful biotech companies are created from a special alchemy of science, business, technology, talent, and capital”

- Carl Hansen, Founder and CEO of AbCellera

Orbital Therapeutics develops RNA medicines. Founded in 2022 spinning out of Beam Therapeutics, the focus is on vaccines, immunomodulation, and protein replacement therapies. The business model is premised on collecting IP spanning different RNA modalities and delivery methods

Illumina sales Illumina sales
in year one: today:
$474,000 $474,000 per hour

Scipher Medicine is a precision immunology company that matches patients with the most effective therapy for them. Developing PrismRA, a blood test that analyzes a patient's molecular signature to identify who is unlikely to respond to TNFi therapy so they can be prescribed an alternative

Iambic Therapeutics, previously known as Entos is a drug discovery company that uses physics-based AI algorithms and high-throughput experimentation to optimize drug candidates and profiles

Dren Bio develops antibody therapies for cancer and autoimmunity. Focusing on biologics designed to selectively target and eliminate pathogenic cells and agents. Founded in 2019, their pipeline is made up of two drug discovery programs

Hypoimmune induced pluripotent stem cell–derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice www.pnas.org/doi/abs/10.1...

M4205, a selective KIT inhibitor. Developed by Merck

KIT is a class III receptor tyrosine kinase. And difficult to target effectively due to its high propensity for both mutations in the KIT gene, and secondary mutations within the ATP-binding pocket

pubs.acs.org/doi/10.1021/...

Bicycle Therapeutics develops bicyclic peptides into drugs. Founded in 2009 by Gregory Winter, who invented phage display, the company has brought this new modality ('bicycles') into the clinic to treat cancer

TAK-279

A phase Ilb oral, once-daily allosteric TYK2 inhibitor

Developed by Nimbus and acquired by Takeda

www.takeda.com/newsroom/new...

Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature's innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases

Deubiquitinase-targeting chimeras for targeted protein stabilization

The paper describes an approach to targeting proteins for stabilization, called DUBTACs - heterobifunctional molecules that consist of a protein-targeting ligand linked to a DUB recruiter

www.nature.com/articles/s41...

"Overcoming the hurdles has built a great faith in me that things can be done to help people with rare diseases. It will drive my optimism forever and my belief in achieving things that seem impossible."

- Henri Termeer, former CEO of Genzyme

Glycolipids from the gut symbiont Bacteroides fragilis are agonists for natural killer T cells and induce their regulatory differentiation led by Garth Cameron & Tram Nguyen from the Dale Godfrey lab pubs.rsc.org/en/content/a...